Ricoh Launches Digital Postcard Tool in Support of Alzheimer's Research
Ricoh has launched an innovative digital postcard tool to help those affected by dementia, most commonly caused by Alzheimer’s disease, stay connected through personalised images.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180612005017/en/
Ricoh Launches Digital Postcard Tool in Support of Alzheimer's Research (Photo: Business Wire)
The tool, which makes use of Ricoh’s proprietary technology and production workflow expertise, sits at the heart of the company’s Printed Memories programme in partnership with Alzheimer’s Research, Europe’s leading dementia research charity.
The Printed Memories portal
People with dementia may become withdrawn and socially isolated, and it can be a challenge for families and carers to preserve the same connection they once had to the person. Photographs and mementos from throughout a person’s life can become powerful reminder of the life they have lived and the people they love. Printed Memories helps keep these connections alive, particularly when families live away from a loved one who has dementia.
Users simply upload a photo of a memory with a loved one onto the Printed Memories platform. They then have the option to write a personal message before converting their photo into a postcard, which is sent directly to the recipient wherever they are based across Europe. A donation of £1 will be collected with all proceeds going to Alzheimer’s Research.
While the Printed Memories portal is primarily targeted at family members and friends of people with dementia, it is open to everyone to use. It is available in English, Spanish, Italian and Polish. More languages will be added over the course of the year.
The back end process has been designed to ensure ultra efficiency and a smooth user experience. Data is received and processed in Ricoh’s facility in Telford, UK. The fully automated end to end production process requires no manual intervention from the arrival of the job through to set up, print, finishing and fulfilment. This ensures portal users receive a consistently efficient service, allowing them to simply enjoy creating their personalised postcard.
Javier Diez-Aguirre, Vice President, Corporate Marketing, CSR & Environment, Ricoh Europe, says: “I am extremely proud of our Printed Memories portal and the broader programme we are running with our friends at Alzheimer’s Research. Thanks to our technology and people, we can help bring families closer together and raise vital funds for Alzheimer’s Research. Dementia, of which Alzheimer’s is the leading cause, is one of the world’s greatest medical challenges and I believe that corporations like Ricoh have an important role to play in raising awareness and making a real impact on the future.”
Timothy Parry, Director of Communications and Partnerships at Alzheimer’s Research, adds: “The generosity, support and technology know-how shared by Ricoh is playing a powerful role in helping those affected by Alzheimer’s and other dementias to stay connected. The Printed Memories portal demonstrates the unique strengths that partnership can unlock in the battle to combat these diseases. Ricoh’s staff can be proud that they are supporting our mission to bring about the first life-changing dementia treatment by 2025 in meaningful ways.”
For more information visit www.printed-memories.com.
Ricoh is empowering digital workplaces using innovative technologies and services enabling individuals to work smarter. For more than 80 years, Ricoh has been driving innovation and is a leading provider of document management solutions, IT services, commercial and industrial printing, digital cameras, and industrial systems.
Headquartered in Tokyo, Ricoh Group operates in approximately 200 countries and regions. In the financial year ended March 2018, Ricoh Group had worldwide sales of 2,063 billion yen (approx. 19.4 billion USD).
For further information, please visit www.ricoh-europe.com .
Join us on Facebook: www.facebook.com/ricoheurope
Follow us on Twitter: www.twitter.com/ricoheurope
Ricoh Europe PLC
Tel: +44 (0) 203 033 3750
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i